PharmaShots | Incisive News in 3 Shots

Subscribe Now

Immutep

Immutep Provides Data from the P-IIb (TACTI-003) Study of Eftilagimod Alfa to Treat Head and Neck Squamous Cell Carcinoma

Immutep Provides Data from the P-IIb (TACTI-003) Study of Eftilagimod Alfa to Treat Head and Neck Squamous Cell Carcinoma

July 12, 2024

Immutep Partners with Merck to Conduct P-III Study of Eftilagimod Alfa (Efti) with Keytruda for Treating NSCLC

Immutep Partners with Merck to Conduct P-III Study of Eftilagimod Alfa (Efti) with Keytruda for Treating NSCLC

June 3, 2024

Immutep Reports P-I Trial (INSIGHT-003) Results of Triple Combination Therapy as 1L Treatment of Non-Small Cell Lung Cancer

Immutep Reports P-I Trial (INSIGHT-003) Results of Triple Combination Therapy as 1L Treatment of Non-Small Cell Lung Cancer

May 25, 2023

Immutep Enters into a Clinical Trial Collaboration with Merck KGaA and Pfizer to Evaluate Eftilagimod Alpha (Efti) for Urothelial Cancer

Immutep Enters into a Clinical Trial Collaboration with Merck KGaA and Pfizer to Evaluate Eftilagimod Alpha (Efti) for Urothelial...

November 30, 2022

Immutep & MSD Published New Interim Data of Eftilagimod Alpha + Keytruda (pembrolizumab) in P-II (TACTI-002) Trial as 2L Treatment of NSCLC at ELCC 2022

Immutep & MSD Published New Interim Data of Eftilagimod Alpha + Keytruda (pembrolizumab) in P-II (TACTI-002) Trial as 2L Treatment...

March 31, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us